B-domain-deleted factor VIII

06/14/2019 - "BMN 270 is an AAV5-based vector for treating hemophilia A that encodes human B domain-deleted factor VIII (FVIII-SQ). "
03/01/2018 - "Following a provincial tender, most subjects with haemophilia A in Quebec switched their treatment to a third-generation recombinant B-domain-deleted factor VIII (FVIII). "
09/01/2003 - "Successful use of B-domain deleted factor VIII for resection of pituitary adenoma in a paediatric patient with severe haemophilia A."
03/01/2021 - "Gene therapy for hemophilia A and B benefited from advancements in the general gene therapy field, such as the development of adeno-associated viral vectors, as well as disease-specific breakthroughs, like the identification of B-domain deleted factor VIII and hyperactive factor IX Padua. "
04/01/2004 - "In the first gene therapy trial for hemophilia A, a non-viral approach was being explored for patients with severe hemophilia A using ex vivo transfected dermal fibroblast expressing B-domain-deleted factor VIII ( BDD-FVIII). "

11/01/2004 - "Meta-analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII."
09/01/2004 - "Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII--a robust meta-analytic finding."

09/01/2003 - "Successful use of B-domain deleted factor VIII for resection of pituitary adenoma in a paediatric patient with severe haemophilia A."

01/01/2023 - "Valoctocogene roxaparvovec delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. "